chronic autoimmune disease
GSK shares promising phase 3 results for linerixibat in PBC-related itch
Pruritus is experienced by up to 90% of patients with the rare liver disease
Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis
The life-long condition affects approximately 1,900 people in Scotland
Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC
Primary biliary cholangitis affects approximately 163,000 people in Europe
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults
The company gained access to the drug through its $4.3bn acquisition of CymaBay
Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis
The rare liver disease affects approximately 15 per 100,000 people in Europe
GSK’s linerixibat shows promise in phase 3 primary biliary cholangitis trial
An estimated 510,000 people will be diagnosed with the rare liver disease globally by 2030
Ipsen shares positive three-year results for Iqirvo in primary biliary cholangitis
The rare liver disease affects approximately 100,000 people in the US
Ipsen’s Iqirvo recommended by NICE to treat rare liver disease primary biliary cholangitis
The disease affects approximately 25,000 people in the UK, the majority of whom are women
Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults
Approximately 25,000 people in the UK are affected by the rare liver disease
Ipsen’s Iqirvo receives EC approval to treat primary biliary cholangitis in adults
The rare liver disease affects approximately nine women for every one man
Gilead’s Livdelzi receives FDA accelerated approval to treat primary biliary cholangitis
The company gained access to the drug through its $4.3bn acquisition of CymaBay in March
Calliditas announces promising results for NOX enzyme inhibitor in rare liver disease
Primary biliary cholangitis is estimated to affect approximately 140,000 patients in the US